1
Clinical Trials associated with DNAJB1-PRKACA peptide vaccine(The Sidney Kimmel Comprehensive Cancer Center)A Pilot Study of a DNAJB1-PRKACA Fusion Kinase Peptide Vaccine Combined With Nivolumab and Ipilimumab for Patients With Fibrolamellar Hepatocellular Carcinoma
The primary objective of the trial is the safety and tolerability of administering a vaccine targeting the DNAJB1-PRKACA fusion kinase, in combination with nivolumab and ipilimumab in patients with unresectable or metastatic FLC and with non-FLC solid tumors and to assess the T-cell response.
100 Clinical Results associated with DNAJB1-PRKACA peptide vaccine(The Sidney Kimmel Comprehensive Cancer Center)
100 Translational Medicine associated with DNAJB1-PRKACA peptide vaccine(The Sidney Kimmel Comprehensive Cancer Center)
100 Patents (Medical) associated with DNAJB1-PRKACA peptide vaccine(The Sidney Kimmel Comprehensive Cancer Center)
100 Deals associated with DNAJB1-PRKACA peptide vaccine(The Sidney Kimmel Comprehensive Cancer Center)